Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2011

View Archived Issues

Phase I trials assess efatutazone in Japanese and Korean patients with advanced solid tumors

Studies provide overview of data on novel antibacterial LFF-571

Posiphen's mechanism of action confirmed in various models

Depomed releases topline data from BREEZE 3 trial of Serada in menopausal hot flashes

Cylene Pharmaceuticals advances CX-5461

FOB Synthesis describes new carbapenem with activity against multidrug-resistant bacteria

New clinical data presented on novel HIV integrase inhibitor

Gene therapy for hemophilia B evaluated in rhesus macaques

Novel lactam acetamides patented by Abbot Laboratories

Catabasis Pharmaceuticals reports novel NF-kappa-B activation inhibitors

Purdue Research Foundation discovers new chemokine CCR5 receptor antagonists

New beta-secretase 1 inhibitors synthesized at Amgen

Dana-Farber Cancer Institute claims new protein kinase inhibitors

Achillion selects clinical candidate from NS5A inhibitor program

Helix BioPharma files clinical hold response with FDA for topical interferon alfa-2b

FDA continues clinical hold on Insmed's study of Arikace in NTM lung disease

Merck & Co. terminates JTT-305 licensing agreement

Mitsubishi Tanabe Pharma gains North American rights to TRK-820

Eisai and Johns Hopkins University enter collaboration

Azelon raises funds to support development of nasal spray for osteoporosis

Ongoing trial assesses modafinil in postoperative cognitive dysfunction

Medgenics and Baxter discuss continuation of Biopump collaboration

Epizyme triggers milestone payment in HMT therapeutic alliance with GSK

Teva Pharmaceutical acquires Cephalon

Migalastat hydrochloride evaluated in female patients with Fabry's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...